SOURCE: Pharming Group N.V.

September 19, 2007 02:23 ET


LEIDEN, NETHERLANDS--(Marketwire - September 19, 2007) -

Dutch government supports BMM partnership

Leiden, The Netherlands, September 19, 2007. Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) today announced that the Dutch government will provide funding of EUR 45 million to the BioMedical Materials program (BMM), as was announced yesterday during the presentation of the national budget for 2008.

BMM is a public-private partnership in the Netherlands that focuses on research and development in the field of biomedical materials. The program has a provisional budget of EUR 90 million and will run for five years. Pharming is one of the participants in this initiative, which originated at DSM and the University of Maastricht. The BMM consortium now comprises over 25 partners, including leading players Philips Research, Organon, Medtronic, FujiFilm Life Science and TNO, along with most of the leading universities and university medical centers in the Netherlands.

BMM's mission is to give the Netherlands an internationally leading position in the field of biomedical materials by developing successful medical applications, obtaining intellectual property rights and publishing scientific papers. Projects carried out by the consortium should lead to innovative new applications and products in the field of biomaterials, and are to be developed further by the individual companies.

Dr. Bruno Giannetti, Chief Operations Officer of Pharming: "Pharming is pleased to be a member of this promising program and supports this initiative, which will likely lead to important innovations in this field. Through our technology and expertise in the fields of tissue engineering and recombinant proteins, in particular fibrinogen and collagen, we will be able to provide important contributions to the program while, at the same time, exploring new opportunities for our technologies and products."

About BMM

The BioMedical Materials program (BMM) is a public-private partnership of the Dutch government, academia and industry that focuses on research and development in the field of biomedical materials. Over the next five years BMM aims to become a world leader in the field of biomedical materials and their use and applications in a clinical environment. The BioMedical Materials program will address four priority disease areas, each addressing specific clinical needs and specific biomedical materials breakthroughs: cardiovascular diseases (incl. consequences of diabetes), oncology (cancer), musculoskeletal, and nephrology. New concepts will be explored in a translational approach, where ideas will be tested from the lab up to and including the proof-of-principle, involving all partners, disciplines and areas of expertise that are required for application in a clinical environment. The clinical need for new therapies will be leading in defining the focus in the research agenda and research topics. A total of around 28 partners have committed themselves to this initiative. A full list of partners and supporters and more information on BMM can be found on

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (MAA under review by EMEA) and human lactoferrin for use in food products (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via its acquisition of DNage). Additional information is available on the Pharming website, and on

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.


Carina Hamaker                Rein Strijker
Investor Voice                Pharming Group NV
T: +31 (0)6 537 499 59        T: +31 (0)71 52 47 400
T: +31 (0)71 52 47 400

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information